Get Premium to unlock powerful stock data
NAS:TCRX (USA)  
TScan Therapeutics Inc logo

TScan Therapeutics Inc

$ 3.06 +0.04 (+1.32%) 10:08 PM EST
P/E:
At Loss
P/B:
0.50
Market Cap:
$ 73.54M
Enterprise V:
$ -61.66M
Volume:
9.32K
Avg Vol (2M):
139.98K
Volume:
9.32K
Market Cap $:
73.54M
PE Ratio:
At Loss
Avg Vol (2-Month):
139.98K
Enterprise Value $:
-61.66M
PB Ratio:
0.50
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

TScan Therapeutics Inc
NAICS : 541714 SIC : 2834
830 Winter Street, Waltham, MA, USA, 02451
Description
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Name Current Vs Industry Vs History
Cash-To-Debt 24.95
Equity-to-Asset 0.87
Debt-to-Equity 0.04
Debt-to-EBITDA -0.11
Interest Coverage N/A
N/A
N/A
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.92
Distress
Grey
Safe
Beneish M-Score 0.75
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
Future 3-5Y Total Revenue Growth Rate Industry Rank 12.88

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 52.4
9-Day RSI 51.4
14-Day RSI 52.17
6-1 Month Momentum % -40.74

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 7.89
Quick Ratio 7.89
Cash Ratio 7.63

Dividend & Buy Back

Name Current Vs Industry Vs History

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -510.88
Net Margin % -510.72
ROE % -76.73
ROA % -34.17
ROIC % -162.38
ROC (Joel Greenblatt) % -346.81
ROCE % -38.97

Financials (Next Earnings Date:2022-08-19 Est.)

TCRX's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:TCRX

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 11.135
EPS (TTM) ($) -2.518
Beta 0
Volatility % 0
14-Day RSI 52.17
14-Day ATR ($) 0.312394
20-Day SMA ($) 3.1135
12-1 Month Momentum % 0
52-Week Range ($) 1.6 - 14.71
Shares Outstanding (Mil) 24.03

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

TScan Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More